K. T. Flaherty, Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med, vol.363, pp.809-819, 2010.

J. A. Sosman, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N. Engl. J. Med, vol.366, pp.707-714, 2012.

M. Das-thakur, Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, vol.494, pp.251-255, 2013.

A. Millet, A. R. Martin, C. Ronco, S. Rocchi, and R. Benhida, Metastatic melanoma: insights into the evolution of the treatments and future challenges, Med. Res. Rev, vol.37, pp.98-148, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01589727

P. A. Ott, F. S. Hodi, and C. Robert, CTLA-4 and PD1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients, Clin. Cancer Res, vol.19, pp.5300-5309, 2013.

E. Blanchet, J. S. Annicotte, and L. Fajas, Cell cycle regulators in the control of metabolism, Cell Cycle, vol.8, pp.4029-4031, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00442943

D. Engelmann and B. M. Putzer, The dark side of E2F1: in transit beyond apoptosis, Cancer Res, vol.72, pp.571-575, 2012.

P. Meng and R. Ghosh, Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?, Cell Death Dis, vol.5, p.1360, 2014.

Y. Ma, A small-molecule E2F inhibitor blocks growth in a melanoma culture model, Cancer Res, vol.68, pp.6292-6299, 2008.

M. Verhaegen, A. Checinska, M. B. Riblett, S. Wang, and M. S. Soengas, E2F1-dependent oncogenic addiction of melanoma cells to MDM2, Oncogene, vol.31, pp.828-841, 2012.

A. and V. , E2F1 in melanoma progression and metastasis, J. Natl. Cancer Inst, vol.102, pp.127-133, 2010.

D. Talantov, Novel genes associated with malignant melanoma but not benign melanocytic lesions, Clin. Cancer Res, vol.11, pp.7234-7242, 2005.

D. Bogunovic, Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival, Proc. Natl. Acad. Sci. USA, vol.106, pp.20429-20434, 2009.

S. Giuliano, Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas, Cancer Res, vol.70, pp.3813-3822, 2010.

P. Corazao-rozas, Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf mutant inhibitor, Oncotarget, vol.4, pp.1986-1998, 2013.

M. A. Nelson, Increased gene copy number of the transcription factor E2F1 in malignant melanoma, Cancer Biol. Ther, vol.5, pp.407-412, 2006.

K. Alexander and P. W. Hinds, Requirement forp27(KIP1) in retinoblastoma protein-mediated senescence, Mol. Cell. Biol, vol.21, pp.3616-3631, 2001.

P. Ji, An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant, Mol. Cell, vol.16, pp.47-58, 2004.

D. M. Thomas, Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma, J. Cell Biol, vol.167, pp.925-934, 2004.

S. Phalke, p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6, Nucleic Acids Res, vol.40, pp.9534-9542, 2012.

P. Falletta, Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma, Genes Dev, vol.31, pp.18-33, 2017.

J. F. Passos, Feedback between p21 and reactive oxygen production is necessary for cell senescence, Mol. Syst. Biol, vol.6, p.347, 2010.

Z. Ji, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth, Clin. Cancer Res, vol.19, pp.4383-4391, 2013.

C. Posch, Combined Inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma, J. Invest. Dermatol, vol.135, pp.2475-2483, 2015.

A. M. Eggermont, A. Spatz, C. Robert, . Cutaneous, and . Melanoma, Lancet, vol.383, pp.816-827, 2014.

T. Botton, In vitro and in vivo anti-melanoma effects of ciglitazone, J. Invest. Dermatol, vol.129, pp.1208-1218, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02194090

A. Lehraiki, Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib, Cell Discov, vol.1, p.15030, 2015.

T. Botton, Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth, Cell Death Differ, vol.18, pp.109-121, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00551041

M. Cerezo, Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance, Cancer Cell, vol.29, pp.805-819, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01357448

A. Lehraiki, Inhibition of melanogenesis by the antidiabetic metformin, J. Invest. Dermatol, vol.134, pp.2589-2597, 2014.

M. Cerezo, Metformin blocks melanoma invasion and metastasis development in a p53-dependent manner, Mol. Cancer Ther, vol.12, pp.1605-1615, 2013.

F. Rouaud, J. L. Boucher, A. Slama-schwok, and S. Rocchi, Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH Analogue, Oncotarget, vol.7, pp.82804-82819, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01604167